AbCellera Biologics (ABCL) Other Working Capital Changes (2020 - 2021)

AbCellera Biologics' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• Quarterly Other Working Capital Changes fell 86.92% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.8 million (down 466.73% YoY) and the FY2025 annual result came in at -$2.2 million, up 63.13% from the prior year.
• Other Working Capital Changes was $1.9 million for Q1 2021 at AbCellera Biologics, up from $1.4 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $1.9 million in Q1 2021 and bottomed at $1.4 million in Q1 2020.
• A 5-year average of -$1.4 million and a median of $149000.0 in 2022 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes slumped 9451.68% — and 2025, when it soared 735.47%.
• AbCellera Biologics' Other Working Capital Changes stood at $149000.0 in 2022, then slumped by 9451.68% to -$13.9 million in 2023, then soared by 64.5% to -$4.9 million in 2024, then advanced by 8.79% to -$4.5 million in 2025, then soared by 138.59% to $1.7 million in 2026.
• Business Quant data shows ABCL's Other Working Capital Changes at $1.7 million in Q1 2026, -$4.5 million in Q4 2025, and $15.8 million in Q3 2025.